Helix
- Industry
- Genomics
- Founded Year
- 2015
- Headquarters
- San Mateo, California, United States
- Employee Count
- 510
Key People
- James Lu - Co-Founder & CEO
- Jim Chou - Chief Technology Officer
- William Lee - Senior Vice President, Chief Science Officer
- Sarah Bobulsky - Chief Financial Officer
- Sheren Chiang - Vice President of People
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in technology and healthcare.
Helix's leadership includes individuals with significant experience in technology and healthcare sectors, contributing to the company's strategic direction and operational success.
- Clinical Need
-
Aspect: Very Strong
Summary: Integrating genomic data into clinical care addresses a critical need for personalized medicine.
The healthcare industry is increasingly recognizing the importance of genomics in personalized medicine, making Helix's offerings highly relevant and necessary.
- Competition
-
Aspect: Somewhat crowded
Summary: The genomics market has several established players, but Helix's unique platform offers differentiation.
The genomics field includes multiple companies; however, Helix's end-to-end platform and partnerships with health systems distinguish it from competitors.
- Technical Challenge
-
Aspect: Predictable
Summary: Helix's proprietary Exome+ assay and sequencing capabilities are well-established.
Helix's technology, including its Exome+ assay, is based on established sequencing methods, reducing technical uncertainties.
- Patent
-
Aspect: Strong
Summary: Helix holds proprietary technologies that provide a competitive advantage.
Helix's proprietary technologies, such as the Exome+ assay, contribute to its unique offerings in the genomics market.
- Financing
-
Aspect: Well-funded
Summary: Helix has secured significant funding from reputable investors.
With over $400 million in funding from investors like Warburg Pincus and Mayo Clinic, Helix is well-positioned financially to execute its strategic plans.
- Regulatory
-
Aspect: 510k/PMA
Summary: Helix operates a CLIA-certified and CAP-accredited sequencing lab, meeting regulatory standards.
Helix's adherence to CLIA and CAP standards demonstrates its commitment to quality and regulatory compliance in genomic testing.
Opportunity Rollup
- Odds of Success
- 3.7
- Peak Market Share
- 4.7
- Segment CAGR
- 10.7%
- Market Segment
- Genomic Testing
- Market Sub Segment
- Population Genomics
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.70 |
| 3 | 1.64 |
| 4 | 3.29 |
| 5 | 4.70 |
Key Takeaway
Helix's strong leadership, proprietary technology, and substantial funding position it well to capitalize on the growing demand for personalized medicine through genomics.